% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • justarook04 justarook04 Jun 17, 2014 4:16 PM Flag

    So the market valued Merck's part in this at 20%?

    Way overreaction. Merck just spent $3.85B on IDIX which could be a "crapshoot". They were after the Ovarian cancer windfall and that is now gone. The lung disease market is much bigger. Anyway, today's surge should have had NOTHING to do with Merck and everything to do about the Phase IIB Lung trial. Now foolish panic has set in (again). We shall see if the Analysts chime in.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.98-0.05(-1.65%)Aug 31 4:00 PMEDT